305 results match your criteria: "and the Comprehensive Cancer Center[Affiliation]"
Sci Transl Med
July 2017
Department of Radiation Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43017, USA. Email:
A skin-penetrant small molecule activates melanin production to protect cells from cancer-inducing ultraviolet damage.
View Article and Find Full Text PDFSci Transl Med
May 2017
Department of Radiation Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43017, USA. Email:
A screening method can identify tumors susceptible to synthetic lethality via PARP inhibition.
View Article and Find Full Text PDFJ Thorac Cardiovasc Surg
July 2017
Department of Thoracic Surgery, St James's University Hospital, Leeds, United Kingdom. Electronic address:
Objective: To compare the incidence of major adverse cardiac events (MACE) and mortality following video-assisted thoracoscopic surgery (VATS) lobectomy in patients with and without coronary artery disease (CAD).
Methods: Multicentre retrospective analysis of 1699 patients undergoing VATS lobectomy (January 2012-March 2015). CAD definition: previous acute myocardial infarct (AMI), angina, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
Sci Transl Med
April 2017
Department of Radiation Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43017, USA. Email:
Increased iron in cancer cells drives selective sensitization of tumors to ascorbate treatment to prolong survival.
View Article and Find Full Text PDFSci Transl Med
March 2017
Department of Radiation Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43017, USA. Email:
Functionally diverse subpopulations of astrocytes have correlates in the neoplastic adult brain.
View Article and Find Full Text PDFInt J Cancer
May 2017
Department of Medicine II, University of Munich, Munich, Germany.
Detection of methylated free-circulating DNA (mfcDNA) for hyperplastic polyposis 1 (HPP1) in blood is correlated with a poor prognosis for patients with metastatic colorectal cancers (mCRC). Here, we analyzed the plasma levels of HPP1 mfcDNA in mCRC patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1 mfcDNA is a suitable prognostic and response biomarker. From 467 patients of the prospective clinical study AIO-KRK-0207, mfcDNA was isolated from plasma samples at different time points and bisulfite-treated mfcDNA was quantified using methylation specific PCR.
View Article and Find Full Text PDFBiomater Sci
December 2016
Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. and Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA and The Center for Clinical and Translational Science, The Ohio State University, Columbus, OH 43210, USA and The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Delivery is the key challenge for siRNA based therapeutics. Here, we report the development of new poly(glycoamidoamine) brush nanomaterials for efficient siRNA delivery. GluN4C10 polymer brush nanoparticles, a lead material, demonstrated significantly improved delivery efficiency for siRNA against factor VII (FVII) in mice compared to poly(glycoamidoamine) brush nanomaterials reported previously.
View Article and Find Full Text PDFMenopause
May 2017
1Departments of Ob/Gyn, Medicine (Geriatrics), and the Comprehensive Cancer Center, The University of Chicago, Chicago, IL 2Department of Ob/Gyn, The University of Chicago, Chicago, IL 3Institute for Mind and Biology, The University of Chicago, Chicago, IL 4Departments of Psychology and Comparative Human Development, The University of Chicago, Chicago, IL 5Department of Public Health Sciences, The University of Chicago, Chicago, IL.
Objective: This work aims to establish current population-based vaginal estrogenization norms for postmenopausal US women.
Methods: Using a US national probability sample of 868 postmenopausal women ages 57 to 85 years (mean age 67.6 ± 0.
Arch Pathol Lab Med
October 2016
From the Departments of Pathology and Laboratory Medicine (Drs Asirvatham and Kleer) and the Comprehensive Cancer Center (Dr Kleer), University of Michigan Hospital and Health Systems, Ann Arbor; and Department of Pathology, CEMIC University Hospital, Buenos Aires, Argentina (Dr Falcone).
Apocrine change in the breast is an extremely common finding. In most cases, the benign or malignant nature of the lesion is easily recognized. Apocrine adenosis is used to describe sclerosing adenosis with apocrine change.
View Article and Find Full Text PDFArch Pathol Lab Med
October 2016
From the Department of Pathology (Drs Udager and Mehra) and the Comprehensive Cancer Center (Dr Mehra), University of Michigan Health System, Ann Arbor; and the Michigan Center for Translational Pathology, Ann Arbor (Dr Mehra).
Molecular and morphologic interrogation has driven a much-needed reexamination of renal cell carcinoma (RCC). Indeed, the recently released 2016 World Health Organization classification now recognizes 12 distinct RCC subtypes, as well as several other emerging/provisional RCC entities. From a clinical perspective, accurate RCC classification may have important implications for patients and their families, including prognostic risk stratification, targeted therapeutics selection, and identification for genetic testing.
View Article and Find Full Text PDFLeukemia
January 2017
Department of Medicine, University of Chicago, Chicago, IL, USA.
In this prospective phase 2 clinical trial conducted by Cancer and Leukemia Group B (CALGB, now the Alliance), we studied decitabine as maintenance therapy for younger adults with acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive induction and consolidation. Given that decitabine is clinically active in AML and with hypomethylating activity distinct from cytotoxic chemotherapy, we hypothesized that 1 year of maintenance therapy would improve disease-free survival (DFS) for AML patients <60 years, who did not receive allogeneic stem cell transplantation in CR1. After blood count recovery from final consolidation, patients received decitabine at 20 mg/m intravenously daily for 4-5 days, every 6 weeks for eight cycles.
View Article and Find Full Text PDFBiopreserv Biobank
December 2016
Department of Pathology and the Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama.
Frequently investigators request that tissues be collected and processed in less than one hour following removal from a patient. Some biorepositories expend significant personnel time and other resources in trying to meet such goals; however, it is unclear whether the perceived benefits of relatively short cold ischemia times warrant these added costs. The literature of human surgical tissues prospectively exposed to cold ischemia at several time points was reviewed to compare the changes in transcripts/genes and microRNA with time of cold ischemia.
View Article and Find Full Text PDFAm J Prev Med
November 2016
Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois; Department of Medicine-Geriatrics, the MacLean Center on Clinical Medical Ethics, and the Comprehensive Cancer Center; University of Chicago, Chicago, Illinois; Urban Health Initiative at the University of Chicago Medicine, Chicago, Illinois.
Introduction: The purpose of this study is to examine the relationship between BMI and access to built environment resources in a high-poverty, urban geography.
Methods: Participants (aged ≥35 years) were surveyed between November 2012 and July 2013 to examine access to common health-enabling resources (grocers, outpatient providers, pharmacies, places of worship, and physical activity resources). Survey data were linked to a contemporaneous census of built resources.
J Surg Oncol
September 2016
Department of Radiation Oncology, The Ohio State University, Columbus, Ohio.
Background And Objectives: The purpose of this study was to determine the pattern and timing of major wound complications (MWCs) in patients at our institution who received multimodality treatment for lower extremity soft tissue sarcoma (LE-STS) and to evaluate the impact of MWCs on tumor control and patient outcomes.
Methods: The medical records of 102 LE-STS patients treated with limb-sparing surgery and radiation therapy were reviewed. MWCs were defined as secondary operations with anesthesia, seroma/hematoma aspiration, admission for IV antibiotics, or persistent deep packing.
Oncotarget
May 2017
Department of Pathology and The Comprehensive Cancer Center, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Breast cancer is the second leading cause of cancer deaths among women. Cannabinoid receptor 2 (CNR2 or CB2) is an integral part of the endocannabinoid system. Although CNR2 is highly expressed in the breast cancer tissues as well as breast cancer cell lines, its functional role in breast tumorigenesis is not well understood.
View Article and Find Full Text PDFNat Rev Genet
May 2016
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
Since the completion of the human genome project in 2003, extraordinary progress has been made in genome sequencing technologies, which has led to a decreased cost per megabase and an increase in the number and diversity of sequenced genomes. An astonishing complexity of genome architecture has been revealed, bringing these sequencing technologies to even greater advancements. Some approaches maximize the number of bases sequenced in the least amount of time, generating a wealth of data that can be used to understand increasingly complex phenotypes.
View Article and Find Full Text PDFNeurology
June 2016
From the Department of Neurology (M.B., L.S., K.V.T.) and the Comprehensive Cancer Center Mainfranken (U.M.), University of Würzburg, Germany.
Objective: To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis.
Methods: This retrospective observational cohort study included all mitoxantrone-treated patients with multiple sclerosis seen at our department between 1994 and 2007. We collected follow-up information on medically confirmed malignancies, life status, and cause of death, as of 2010.
Sci Rep
April 2016
Department of Medicine, Section of Hematology/Oncology and the Comprehensive Cancer Center, University of Chicago, Chicago, IL, 60637, USA.
Malignant mesothelioma (MM), is an intractable disease with limited therapeutic options and grim survival rates. Altered metabolic and mitochondrial functions are hallmarks of MM and most other cancers. Mitochondria exist as a dynamic network, playing a central role in cellular metabolism.
View Article and Find Full Text PDFCancer Discov
May 2016
Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Unlabelled: Cytogenetically normal acute myeloid leukemia (CN-AML) represents nearly 50% of human AML. Co-occurring mutations in the de novo DNA methyltransferase DNMT3A and the FMS related tyrosine kinase 3 (FLT3) are common in CN-AML and confer a poorer prognosis. We demonstrate that mice with Flt3-internal tandem duplication (Flt3(ITD)) and inducible deletion of Dnmt3a spontaneously develop a rapidly lethal, completely penetrant, and transplantable AML of normal karyotype.
View Article and Find Full Text PDFBioconjug Chem
March 2016
Division of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, ‡Department of Biomedical Engineering, §The Center for Clinical and Translational Science, and ∥The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
Chemically modified nucleotides play significant roles in the effectiveness of mRNA translation. Here, we describe the synthesis of two sets of chemically modified mRNAs [encoding firefly Luciferase (FLuc) and enhanced green fluorescent protein (eGFP), respectively], evaluation of protein expression, and correlation analysis of expression level under various conditions. The results indicate that chemical modifications of mRNAs are able to significantly improve protein expression, which is dependent on cell types and coding sequences.
View Article and Find Full Text PDFLeuk Lymphoma
September 2016
c City of Hope Comprehensive Cancer Center , Gehr Family Center for Leukemia, Duarte , CA , USA.
Targeting aberrant tyrosine kinase activity may impact clinical outcome in acute myeloid leukemia (AML). We conducted a phase I study of the tyrosine kinase inhibitor midostaurin with bortezomib alone and in combination with chemotherapy in patients with AML. Patients on dose levels 1 and 2 (DL1 & 2) received midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.
View Article and Find Full Text PDFArch Pathol Lab Med
October 2015
From the Department of Pathology (Drs Magers, Udager, and Mehra), and the Comprehensive Cancer Center (Dr Mehra), University of Michigan Health System, Ann Arbor; and the Michigan Center for Translational Pathology, Ann Arbor (Dr Mehra).
Translocation-associated renal cell carcinoma (t-RCC) is a relatively uncommon subtype of renal cell carcinoma characterized by recurrent gene rearrangements involving the TFE3 or TFEB loci. TFE3 and TFEB are members of the microphthalmia transcription factor (MiT) family, which regulates differentiation in melanocytes and osteoclasts, and MiT family gene fusions activate unique molecular programs that can be detected immunohistochemically. Although the overall clinical behavior of t-RCC is variable, emerging molecular data suggest the possibility of targeted approaches to advanced disease.
View Article and Find Full Text PDFVaccines (Basel)
July 2015
Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Despite the promise of targeted therapies, there remains an urgent need for effective treatment for esophageal cancer (EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs have significant problems of toxicity, safety, selectivity, efficacy and development of resistance. In this manuscript, we demonstrate that rationally designed peptide vaccines/mimics are a viable therapeutic strategy for blocking aberrant molecular signaling pathways with high affinity, specificity, potency and safety.
View Article and Find Full Text PDFPLoS One
May 2016
Department of Pathology, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, Ohio, United States of America; Department of Urology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi Province, The People's Republic of China; National Prion Disease Pathology Surveillance Center, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, Ohio, United States of America; Department of Neurology, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, Ohio, United States of America; National Center for Regenerative Medicine, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, Ohio, United States of America; State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, The People's Republic of China.
The cellular prion protein (PrPC), a protein most noted for its link to prion diseases, has been found to play a protective role in ischemic brain injury. To investigate the role of PrPC in the kidney, an organ highly prone to ischemia/reperfusion (IR) injury, we examined wild-type (WT) and PrPC knockout (KO) mice that were subjected to 30-min of renal ischemia followed by 1, 2, or 3 days of reperfusion. Renal dysfunction and structural damage was more severe in KO than in WT mice.
View Article and Find Full Text PDFJ Natl Cancer Inst
November 2015
Department of Medicine (PG, DL, FW, BL, SK, JW, MLM, RSH), Committee on Clinical Pharmacology and Pharmacogenomics (MLM, RSH), and the Comprehensive Cancer Center (MLM, RSH), University of Chicago, Chicago, IL; Oncology Clinical Research, Merck Research Laboratories, North Wales, PA (AL, MN, MC, JH).
Background: Many disparate biomarkers have been proposed as predictors of response to histone deacetylase inhibitors (HDI); however, all have failed when applied clinically. Rather than this being entirely an issue of reproducibility, response to the HDI vorinostat may be determined by the additive effect of multiple molecular factors, many of which have previously been demonstrated.
Methods: We conducted a large-scale gene expression analysis using the Cancer Genome Project for discovery and generated another large independent cancer cell line dataset across different cancers for validation.